Skip to main content

BioMedNewsBreaks — Renovaro BioSciences Inc. (NASDAQ: RENB) CEO Featured Guest in Recent Proactive Interview

Renovaro BioSciences (NASDAQ: RENB) (formerly NASDAQ: ENOB), an advanced, preclinical biotechnology firm in cell, gene and immunotherapy focused on solid tumors with short life expectancy, was featured in a recent Proactive interview. Mark Dybul, CEO of Renovaro, joined host Steve Darling to talk about the company and its achievements and potential. Specifically, the two talked about the company’s recent signing of a definitive agreement to merge with GEDiCube, a United-Kingdom-based medical artificial intelligence (“AI”) company renowned for its contributions to the early detection and remission of cancer, as well as expedited drug discovery. During the interview, Dybul discussed the plan to rebrand GEDiCube as Renovaro.AI and then have the two entities work together to accelerate diagnosis processes, improve the efficacy of treatments, pioneer new therapies, and broaden the availability of vital technologies for cancer and other diseases.

Dybul also mentioned that although Renovaro is focused on pancreatic cancer research, the company is planning to extend its focus to include other solid tumors that are typically associated with a short life expectancy. Part of that expansion will include making those tumors as part of the first human phase I/IIa studies anticipated to commence by mid-2024. Dybul also talked about the potential of GEDiCube’s AI technology to support the company’s focus of upcoming human trials on those cancers that are most amenable to treatment. In addition, the company expects the technology to supplement the database of crucial markers for early diagnosis and tracking disease progression, consequently furthering the development of novel iterations of Renovaro’s treatment methodologies and the discovery of new therapeutic options.

To view the interview, visit

To view the full press release, visit

About Renovaro BioSciences Inc.

Renovaro BioSciences has developed advanced cell, gene and immunotherapy platforms designed to renew the body’s natural tumor-fighting capabilities against cancer and infectious diseases. For more information about the company, visit

NOTE TO INVESTORS: The latest news and updates relating to RENB are available in the company’s newsroom at

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published:

San Francisco, CA
415.949.5050 Office

BioMedWire is powered by IBN

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.